Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer.
Moriya T, Hamaji M, Yoshizawa A, Miyata R, Noguchi M, Tamari S, Chiba N, Miyamoto H, Toyazaki T, Tanaka S, Yamada Y, Yutaka Y, Nakajima D, Ohsumi A, Menju T, Date H.
Moriya T, et al. Among authors: tamari s.
Interact Cardiovasc Thorac Surg. 2022 Feb 21;34(3):416-423. doi: 10.1093/icvts/ivab283.
Interact Cardiovasc Thorac Surg. 2022.
PMID: 34652430
Free PMC article.